Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
Eric Kauffman(Roswell Park Comprehensive Cancer Center), Ramaprasad Srinivasan(National Cancer Institute)
Cited by 30
Related Papers
Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
|Oncotarget|2017|88
Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation
|Free Radical Biology and Medicine|2018|22
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
|Clinical Cancer Research|2022|22
Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma
|Journal of Experimental & Clinical Cancer Research|2022|12